The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol tests oral probiotics plus topical secretome as add-ons to standard acne care. According to BMJ Open, it is a Phase 2 double-blind randomized trial with four parallel arms the 2026 protocol. Secretome here means a serum made from signals released by mesenchymal stromal cells. The ICH GCP registry describes it as a topical agent meant to calm inflammation and support repair alongside antibiotics such as topical clindamycin.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What do the four arms test?
- Who is in the trial and where?
- What treatments and skin checks are used?
- What should you do while results are pending?
What do the four arms test?
Veeva Clinical Trials lists four add-on groups built on standard therapy the NCT06925386 registry entry. One group gets active probiotic with placebo secretome. One gets placebo probiotic with active secretome.
One gets both actives, and one gets double placebo. This layout separates each add-on effect. You can see probiotic alone, secretome alone, and the pair against placebo. For readers, that makes any later result easier to read than a single mix would.
Who is in the trial and where?
The ICH GCP registry notes 64 patients with mild-to-moderate acne vulgaris the NCT06925386 record. The same registry places care at the Dermatology and Venereology Department of Bali Mandara General Hospital in Indonesia.
Veeva Clinical Trials describes an 8-week, single-center protocol, so the group stays tight but narrow. Findings would apply most directly to similar mild-to-moderate cases, not severe or widespread acne. Readers outside this care setting should treat later results as early clues, not buying guides.
What treatments and skin checks are used?
BMJ Open lists the oral product as HEXBIO granules. It contains Lactobacillus acidophilus BCMC 12130, L. casei BCMC 12313 and L. lactis BCMC 12451. It also contains Bifidobacterium bifidum BCMC 02290, B.
longum BCMC 02120 and B. infantis BCMC 02129. BMJ Open sets treatment at 8 weeks with baseline and post-therapy checks of acne severity, faecal microbiome, skin microbiome and gut-skin measures. Veeva Clinical Trials lists the primary outcome as fewer comedones and inflammatory lesions assessed by Yolov8. Secondary checks include tryptophan metabolites, collagen, pH, moisture, sebum and IL-6.
What should you do while results are pending?
Veeva Clinical Trials lists the registry status as not yet enrolling. With 64 patients at one center over 8 weeks, the protocol can only give early signals.
It offers no efficacy or safety results yet for shoppers to act on. Stick with your current prescribed routine and do not swap in a probiotic or secretome product to copy the trial. Use this waiting time to make your next dermatology visit more useful:.
- Bring your lesion pattern, current topicals, and antibiotic history.
- Ask whether gut-skin approaches fit your mild-to-moderate acne.
- Ask what 8-week check-ins for comedones, oil, moisture, and redness would show.
You Might Also Like
- The 2026 Oral Probiotic and Topical Secretome Acne Trial Protocol: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Why the 2026 Probiotic and Secretome Paper Reports No Trial Results Yet: A Source-Checked 2026 Briefing for Adults With Persistent Acne
- Probiotics for Acne in a 2026 Systematic Review and Meta-Analysis: What Researchers Still Need to Learn for Adults With Persistent Acne